Loading...

Lee's Pharmaceutical Holdings Limited

0950.HK•HKSE
Healthcare
Drug Manufacturers - Specialty & Generic
HK$1.41
HK$-0.03(-2.08%)

Lee's Pharmaceutical Holdings Limited (0950.HK) Stock Overview

Explore Lee's Pharmaceutical Holdings Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 71.4/100

Key Financials

Market Cap830.3M
P/E Ratio8.92
EPS (TTM)$0.16
ROE0.06%
Fundamental Analysis

AI Price Forecasts

1 Week$1.43
1 Month$1.38
3 Months$1.42
1 Year Target$0.91

0950.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Lee's Pharmaceutical Holdings Limited (0950.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 69.41, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.91.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 8.92 and a market capitalization of 830.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

69.41RSI (14)
0.04MACD
41.97ADX
Revenue Growth
32.95%
↑ 32.95%
Profit Growth
HK$0.16
↑ 457.55%
EPS Growth
HK$0.16
↑ 463.38%
Operating Margin
8.08%
↑ 159.78%
ROE
5.53%
↑ 457.55%
Dividend Yield
0.00%
↑ 66.66%
Analyst Recommendations data is not available for 0950.HKAnalyst Recommendations details for 0950.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders. The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Aloxi and Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renaltransplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis. This segment also offers Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution to treat primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.

CEO

Siu Fong Lee

Employees

1,022

Headquarters

Building 20E, Sha Tin

Founded

2002

Frequently Asked Questions

;